ISebe leHlabathi

Ngomhla wama-20 kweyeThupha ngo-2025, i-Abbisko Therapeutics ibhengeze ukuba iZiko loVavanyo lwaMayeza (i-CDE) le-China National Medical Products Administration (i-NlPA) livumile isicelo se-lND somthinteli wophando we-PD-1 womlomo ka-Abbisko, i-ABSK043, kunye ne-Shanghai Alist Pharmaceuticals KRAS ...Funda ngokugqithisileyo»

Kutshanje, uphando lwe-Antengene's Phase I/II CLINCH lwe-ATG-022 (CLDN18.2 antibody-drug conjugate), isigulane esikhulileyo esinomhlaza wesisu oqhubele phambili kwimigca emininzi ye-chemotherapy, i-immunotherapy kunye nonyango olujoliswe kuyo nangona i-metastases eninzi ifumene impendulo epheleleyo (CR) emva...Funda ngokugqithisileyo»

Ngomhla we-13 kweyeThupha, ngowama-2025, iPacific Time, iwebhusayithi esemthethweni yeNgqungquthela yeHlabathi yoMhlaza weMiphunga ka-2025 (WCLC) ikhuphe izishwankathelo zophando ezikhethiweyo zengqungquthela yalo nyaka, Phakathi kwezinto eziphambili sisishwankathelo esihlaziyiweyo sovavanyo lokuqala lweklinikhi lweSigaba soku-1 ebantwini lwe-HLX43, i-PD-L1 ADC kaHenlius. A...Funda ngokugqithisileyo»

Ngomhla wesi-7 kweyeThupha, iZiko loVavanyo lwaMayeza (i-CDE) le-National Medical Products Administration (i-NMPA) libhengeze ukuba inaliti ye-PA3-17 icetyisiwe ukuba ifakwe kunyango oluphambili, olujoliswe kunyango lwezigulane zabantu abadala abane-lymph ebuyela umva/engashukumiyo ye-T-cell...Funda ngokugqithisileyo»

Ngomhla we-11 kweyeThupha, iZiko loVavanyo lwaMayeza (i-CDE) le-National Medical Products Administration (i-NMPA) libonise ukuba isicelo se-InxMed seethebhulethi ze-IN10018 sicetyisiwe ukuze sisetyenziswe njengendlela yonyango oluphucukileyo, olujoliswe ekudibaneni ne-D-1553 ukunyanga i-KRA ephucukileyo okanye eguqukileyo...Funda ngokugqithisileyo»

UMnu. X sisigulana esikwiminyaka yakhe engama-40 ubudala esifunyaniswe sine-acral melanoma. Emva kotyando olukhulu emva kokufunyaniswa kwakhe ngo-2015, imeko yakhe yahlala izinzile kangangeminyaka elithoba. Ngelishwa, malunga nonyaka ophelileyo, isifo sakhe saphinda savela kunye ne-metastases kwimiphunga yomibini. Nangona wafumana i-inguinal kunye ne-pelvic l...Funda ngokugqithisileyo»

Ngomhla wama-31 kuJulayi, i-AstraZeneca kunye ne-Merck & Co. babhengeze ngokudibeneyo ukuba i-inhibitor yabo ye-PARP iLynparza, kunye ne-Abiraterone kunye ne-prednisolone, ivunyiwe eTshayina kunyango lwezigulane zabantu abadala abanomhlaza we-prostate onganyangekiyo yi-metastatic castration (mCRPC) abane-germline okanye ezinye iintlobo ze-germline...Funda ngokugqithisileyo»

Ngomhla wama-31 kuJulayi, ngo-2025, i-ImmuneOnco Biopharmaceuticals yabhengeza idatha yokuqala yokhuseleko kunye nokusebenza kakuhle evela kwiSigaba sesi-2 sophando oluvulekileyo, oluneziko ezininzi lwe-IMM2510 kunye ne-chemotherapy kwizigulana ezikwicala elingaphambili ezine-advanced non-small cell lung cancer (NSCLC) eyenziwe eTshayina. Ukusukela nge-1 kuJulayi, ngo-2025,...Funda ngokugqithisileyo»

Ngomhla wama-30 kuJulayi, i-National Medical Products Administration (NMPA) yavuma ngokusesikweni ukuthengiswa kwe-HICARA kunyango lwezigulane zabantu abadala abane-relapse okanye i-refractory large B-cell lymphoma (r/r LBCL) abaye bafumana iindlela ezimbini okanye ngaphezulu zonyango lwenkqubo. Oku kuquka i-diffuse large B-cell ...Funda ngokugqithisileyo»

Kutshanje, isigulane esinomhlaza wepancreatic oqhubele phambili nowawungazange uphumelele kwiindlela ezininzi zonyango zangaphambili sifumene ukuncipha kwethumba emva kokufumana unyango lweeseli ze-KD-496 CAR-T, kwaye ukukhululwa okuqinisekisiweyo kugcinwe kwiintsuku ezili-180 emva konyango. Okwangoku, kusekho iimvavanyo ezininzi zeklinikhi zesifo esitsha...Funda ngokugqithisileyo»

Ngomhla we-16 kweyeKhala, iphephancwadi lehlabathi eliphambili iNature Medicine lapapasha idatha yophando kwi-SHR-A1904, i-antibody-drug conjugate (ADC) ejolise kwi-claudin 18.2 (CLDN18.2), yokunyanga umhlaza wesisu oqhubekileyo okanye umhlaza we-gastroesophageal junction (GC/GEJC). Abaphandi benze uvavanyo lokuqala...Funda ngokugqithisileyo»

Nge-17 kaJulayi 2025 – I-Innovent Biologics ibhengeze ukuba iNature Medicine ipapashe iziphumo zophando lweklinikhi lweSigaba soku-1 se-IBI343, i-anti-CLDN18.2 ADC entsha, yonyango lwe-advanced gastric/gastroesophageal junction (G/GEJ) adenocarcinoma. Ipapasho kweli candelo liphambili lamazwe ngamazwe...Funda ngokugqithisileyo»